John Villano is an Oncology physician affiliated with University of Kentucky. OpenAlex indexes 251 publications with 10,573 citations (h-index 43); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Uk Medical Oncology
800 Rose Street, Cc401 Roach Building
Lexington, KY 405360093
Telephone
859-323-6522Provider last certified this registry record 1 Dec 2020.
Clinical trials
- Pembro+Chemo in Brain Mets
Sponsor: John L. Villano, MD, PhD
- Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
Sponsor: John R van Nagell
- Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
Sponsor: John L. Villano, MD, PhD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Novocure Inc.Program year20254 payments
- Caris MPI, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
42.9%Phenothiazine15.4%Prochlorperazine Maleate100%Part D≥43 patientsOther antiepileptics11.8%Levetiracetam100%Part D≥20 patients+ 4 more classes in this area
Cancer & immunology
20.3%Kinase inhibitor13.7%Koselugo22%Imatinib Mesylate20%Tagrisso20%Mekinist19%Tafinlar19%Part D<11 patientsIsocitrate Dehydrogenase 1 Inhibitor6.6%Tibsovo52%Voranigo48%Part D<11 patientsMetabolism & gastrointestinal
16.2%Serotonin-3 Receptor Antagonist13.5%Ondansetron Hcl100%Part D≥34 patientsSubstance P/Neurokinin-1 Receptor Antagonist2.8%Aprepitant100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2013–2014 per NIH RePORTER. The latest:
- Clinical characteristics and patterns of care for rare brain tumor sub-types
University of Kentucky
FY2014$74,116R03CA156561 - Clinical characteristics and patterns of care for rare brain tumor sub-types
University of Kentucky
FY2013$86,578R03CA156561
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David Moliterno, MD
University of Kentucky
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
Phillip Tibbs
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”